TAK 137

Drug Profile

TAK 137

Alternative Names: AMPA receptor potentiator - Takeda; TAK-137

Latest Information Update: 04 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda
  • Class Neuropsychotherapeutics
  • Mechanism of Action AMPA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Neurological disorders; Psychiatric disorders

Most Recent Events

  • 15 May 2015 Discontinued - Phase-I for Attention-deficit hyperactivity disorder (In adults) in USA (PO)
  • 15 May 2015 Discontinued - Phase-I for Neurological disorders (In volunteers) in USA (PO)
  • 15 May 2015 Discontinued - Phase-I for Psychiatric disorders (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top